Loading
Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President.
Sandra Demaria is Vice President of the Society for Immunotherapy of Cancer for 2025-2026 and a professor at Weill Cornell Medicine. Her laboratory studies how radiotherapy modulates anti-tumour immunity and how it can be combined with immune checkpoint blockade, with a strong focus on breast cancer. She is a widely cited contributor to the field of radiation-induced in situ vaccination.
| Title | Journal | Year |
|---|---|---|
| Role of Local Radiation Therapy in Cancer Immunotherapy | JAMA Oncology | 2015 |
| Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift | JNCI: Journal of the National Cancer Institute | 2013 |
| Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells | The Journal of Immunology | 2008 |
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
Shares the tags leadership, clinician-scientist, immunotherapy.
Shares the tags leadership, clinician-scientist, radiotherapy.
Shares the tags leadership, clinician-scientist, immunotherapy.
Shares the tags clinician-scientist, immunotherapy, radiotherapy.